1st described in the 5th century BC by Hippocrates
1613, Spain experienced an epidemic of diphtheria. The year is known as El Año de los Garrotillos (The Year of Strangulations) in the history of Spain
1735, New England epidemic
1826, French epidemic which spread to England
1826, Pierre Bretonneau gave the disease the name diphthérite (from Greek διφθέρα, diphthera 'leather') describing the appearance of pseudomembrane in the throat
the illness was referred to as “diphtheritic croup”, “true croup”, or sometimes simply as “croup”
given it is now rare, the term croup is now reserved for the common viral condition of
croup
1856, epidemic in California
1878, Queen Victoria's daughter Princess Alice and her family became infected with diphtheria, causing two deaths, Princess Marie of Hesse and by Rhine and Princess Alice herself.
1882, the bacterium was identified by Edwin Klebs and named it Klebs–Loeffler bacterium.
1884, Friedrich Loeffler was the first person to cultivate C. diphtheriae and used Koch's postulates to prove association between C. diphtheriae and diphtheria, and showed that the bacillus produces an exotoxin.
1885, Joseph P. O'Dwyer introduced the O'Dwyer tube for laryngeal intubation in patients with an obstructed larynx, replacing tracheostomy as the emergency treatment
1888, Roux and Yersin showed that a substance produced by C. diphtheriae caused symptoms of diphtheria in animals
1890, Shibasaburo Kitasato and Emil von Behring immunized guinea pigs with heat-treated diphtheria toxin and showed that an “antitoxin” made from serum of immunized animals could cure the disease in non-immunized animals.
1894, successful treatment of human patients with horse-derived antitoxin began after production and quantification of antitoxin had been optimized.
1897, Paul Ehrlich developed a standardized unit of measure for diphtheria antitoxin.
1901, 10 of 11 inoculated St. Louis children died from contaminated diphtheria antitoxin. The horse from which the antitoxin was derived died of tetanus. This played an important part in initiating US federal regulation of biologic products.
1904, Ruth Cleveland died of diphtheria at the age of 12 years in Princeton, New Jersey. Ruth was the eldest daughter of former President Grover Cleveland
1906, Clemens Pirquet and Béla Schick described serum sickness in children receiving large quantities of horse-derived antitoxin.
1911, Béla Schick developed the Schick test to detect pre-existing immunity to diphtheria in an exposed person. Only those who had not been exposed to diphtheria were vaccinated.
1919, in Dallas, Texas, 10 children were killed and 60 others made seriously ill by toxic antitoxin which had passed the tests of the New York State Health Department
In the 1920s, each year an estimated 100,000 to 200,000 diphtheria cases and 13,000 to 15,000 deaths occurred in the United States.
1930's, widespread vaccination pushed cases in the United States down from 4.4 per 100,000 inhabitants in 1932 to 2.0 in 1937
1974, the WHO included DPT vaccine in their immunisation schedules
2015, 4,500 cases were officially reported worldwide with 2100 deaths, down from 8000 deaths in 1990, and down from nearly 100,000 reported cases in 1980.
prior to 1980 there were approx. a million cases a year
2017, an outbreak of occurred in Indonesia with more than 600 cases found and 38 fatalities
2022, largest diphtheria epidemic in Western Europe for 70 years with 362 notified cases that year (98% male, median age 18, 96% were recent migrants who appeared to have picked it up en route, 77% were cutaneous, 15% were more severe resp. forms) and in 2023 spread to other vulnerable populations in several European countries. This strain had genetic links to an epidemic that occurred in Germany in 2025. By June 2025, there had been a total of 536 cases, including at least three deaths, reported in Europe.
1)
July 2022, there were 2 cases in children in northern NSW - the 1st cases in NSW this century
post-Covid-19 globally decreased immunization uptake rates pose further epidemic risks
see
vaccines for history of vaccine development